根据公告，报告期内，沃森生物国内疫苗产品收入降幅收窄，趋于平稳，出口疫苗产品收入较上年同期 增长约35%，同时叠加降本增效等系列管控措施，实现净利润较上年同期增长。 北京商报讯（记者 王寅浩 宋雨盈）1月28日，沃森生物发布2025年业绩预告，预计2025年归属于上市公 司股东的净利润为1.6亿—1.9亿元，同比增长13%—34%；扣除非经常性损益后的净利润为8500万— 9900万元，同比下降9%—22%。 ...

Core Viewpoint - Jiukang Bio (300406) has announced a significant decline in its expected net profit for 2025, projecting a decrease of 59.07% to 66.21% year-on-year [1] Financial Performance - The company expects the net profit attributable to shareholders to be between 180 million to 218 million yuan for 2025 [1] - The net profit after deducting non-recurring gains and losses is projected to be between 171 million to 211 million yuan, reflecting a year-on-year decline of 59.48% to 67.16% [1]

智通财经APP讯，九强生物(300406.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 1.8亿元至2.18亿元，同比下降59.07%至66.21%;扣除非经常性损益后的净利润1.71亿元至2.11亿元，同比 下降59.48%至67.16%。 ...

Core Viewpoint - He Yuan Bio (688765.SH) expects a net profit attributable to shareholders of the parent company to be between -167 million and -143 million yuan for the year 2025 [1] Group 1: Financial Performance - The main reason for the performance change is the rapid growth in sales revenue following the approval and market introduction of the product Aofumin (recombinant human albumin injection) [1] - The production line for the annual output of 10 tons of recombinant human albumin raw liquid and preparations is still in the capacity ramp-up phase, with capacity expected to be gradually released [1] - Despite these factors, the company remains in a state of overall performance loss due to continued high levels of R&D investment [1]

每经AI快讯，1月28日，沃森生物(300142.SZ)公告称，预计2025年归属于上市公司股东的净利润为1.60 亿元~1.90亿元，比上年同期增长13.00%~34.00%。业绩变动主要系国外疫苗出口收入增长约35%，国内 收入降幅收窄，叠加降本增效及运营管理能力提升；非经常性损益约8,000万元，同比增加。 ...

自去年8月8日盘中触及19.90港元阶段性高点后，博安生物(06955)的股价便开启了一轮长达5个多月的下跌行情。今年1月5日盘中，博安生物股价触及年内新 低8.15港元，让这段下跌行情的股价高低振幅达到59.05%。 智通财经APP观察到，得益于去年上半年的上涨行情，即使在去年年末市值仅剩53.12亿港元的情况下，博安生物依旧凭借其2025年第二期港股通检讨期内 的65.65亿港元日均市值，在当时港股通调出门槛60.26亿港元上顺利卡位，实现成功"保通"。 然而，这根大阳线并未提振市场情绪，在接下来的行情中，技术面上，博安生物的BOLL线出现了明显的收窄趋势，引导股价持续震荡下跌，而公司股价也 基本沿BOLL线中下轨作机械震荡，且整体走势呈现出无量空跌状态。在这段长达4个月的持续低价行情中，威美控股甚至仅有4个交易日的日成交量超过 1000万股，市场交投情绪较此前明显更加低迷。 即使在去年11月27日出现了一波冲击BOLL线上轨的走势，但均未观察到明显的成交量放大支持，也没有形成有效实体K线突破，在技术面上属于典型的 BOLL线指标"假突破"，后续公司股价依旧震荡下跌至今年1月2日的盘中低点。 结合量能来看 ...

Core Viewpoint - He Yuan Bio (688765.SH) is expected to report significant losses in 2025, with total profit estimated between -167 million to -143 million yuan, and net profit attributable to shareholders also projected in the same range [1] Financial Performance - The company anticipates a revenue of 45 million to 50 million yuan for 2025, representing a year-on-year increase of 78.46% to 98.29% [1] - After excluding non-recurring gains and losses, the net profit attributable to shareholders is expected to be between -191 million to -162 million yuan [1] Key Factors Influencing Performance - The rapid growth in sales revenue is attributed to the market introduction of the product "Aofumin" (recombinant human albumin injection) [1] - The production line for the related product, with an annual capacity of 10 tons of recombinant human albumin, is still in the ramp-up phase, with capacity expected to gradually increase [1] - The company continues to maintain high levels of investment in research and development, contributing to the overall loss during the reporting period [1]

Group 1 - The company, JieTe Bio (688026.SH), announced its first share buyback on January 28, 2026, through the Shanghai Stock Exchange [1] - A total of 272,799 shares were repurchased, representing 0.19% of the company's total share capital [1] - The buyback was executed at a maximum price of 18.43 yuan per share and a minimum price of 18.05 yuan per share, with a total expenditure of 4.9714 million yuan (excluding transaction commissions) [1]

Core Viewpoint - He Yuan Bio is expected to report a net loss of between 143 million to 167 million yuan for the year 2025, indicating ongoing financial challenges despite product launches and revenue growth [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -191 million to -162 million yuan for 2025 [1] - The overall performance remains in a loss state during the reporting period due to various factors [1] Product Development - The product "Aofumin" (recombinant human albumin injection) has been approved for market entry, contributing to rapid revenue growth [1] - The production line for the annual output of 10 tons of recombinant human albumin is still in the capacity ramp-up phase, with gradual capacity release expected [1] Research and Development - The company continues to maintain high levels of investment in research and development [1]

Core Viewpoint - The company Shutaishen (300204.SZ) expects a net profit attributable to shareholders in 2025 to be between -85.33 million and -69.81 million yuan, with a net profit excluding non-recurring gains and losses estimated between -90.56 million and -74.09 million yuan, and operating revenue projected to be between 198.31 million and 242.38 million yuan [1] Group 1 - During the reporting period, the company's production and operational activities were normal, and it actively engaged in various marketing and market exploration efforts, resulting in slight growth in sales revenue and volume of the product Su Tai [1] - The revenue from the product Shutaqing decreased due to external environment and industry policy factors; the company is exploring multiple channels for the Shutaqing product market and focusing on expanding the marketing efforts for polyethylene glycol series products, including "Compound Polyethylene Glycol (3350) Electrolyte Powder (Shusitong)," "Compound Polyethylene Glycol (3350) Electrolyte Oral Solution (Shuyi Qing)," and "Compound Polyethylene Glycol (3350) Electrolyte Vitamin C Powder (Shuchang Qing)" [1] - The company expects non-recurring gains and losses for the year 2025 to be approximately 4.75 million yuan, with specific data to be disclosed in the 2025 annual report [1]